Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, Biocon has informed about submission of the press release titled ‘Biocons Biologics Drug Products Facility in Bengaluru Receives EIR from US FDA’.
The above information is a part of company’s filings submitted to BSE.